Doxorubicin and Lapatinib Combination Nanomedicine for Treating Resistant Breast Cancer

Wang, Huiyuan; Li, Feng; Du, Chengan; Wang, Huixin; Mahato, Ram I.; Huang, Yongzhuo

doi:10.1021/mp400687w

Cited by 74 publications

(36 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lapatinib has also been reported with the ability to inhibit the activity of drug efflux transporters. Based on the amphiphilic poly (ethylene glycol)-block-poly (2-methyl-2-benzoxycarbonylpropylene carbonate) polymers, we developed the DOX micelles and lapatinib micelles, simultaneously, to codeliver DOX and lapatinib in treating multidrug-resistant breast cancer 69 . The results of fluorescence microscopy and flow cytometry showed that coadministration of the DOX micelles and lapatinib micelles can enhance DOX uptake in the MCF-7/ADR cells overexpressing drug efflux transporters but not MCF-7 cells low-expressing drug efflux transporters.…”

Section: Nanotechnology-based Combination Therapymentioning

confidence: 99%

Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer

Zhang

Liu

Cui

et al. 2017

Cancer Biology & Medicine

Self Cite

102

View full text Add to dashboard Cite

Multidrug resistance (MDR) is a major obstacle to successful cancer treatment and is crucial to cancer metastasis and relapse. Combination therapy is an effective strategy for overcoming MDR. However, the different pharmacokinetic (PK) profiles of combined drugs often undermine the combination effect in vivo, especially when greatly different physicochemical properties (e.g., those of macromolecules and small drugs) combine. To address this issue, nanotechnology-based codelivery techniques have been actively explored. They possess great advantages for tumor targeting, controlled drug release, and identical drug PK profiles. Thus, a powerful tool for combination therapy is provided, and the translation from in vitro to in vivo is facilitated. In this review, we present a summary of various combination strategies for overcoming MDR and the nanotechnology-based combination therapy.

show abstract

Section: Nanotechnology-based Combination Therapymentioning

confidence: 99%

Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer

Zhang

Liu

Cui

et al. 2017

Cancer Biology & Medicine

Self Cite

102

View full text Add to dashboard Cite

show abstract

“…Clinical treatments involving a single drug have proven short-lived due to the emergence of resistant cancer cells. A major strategy for overcoming drug resistance is combination therapy 15 16 17 . Given the effectiveness of PL in cancer cell lines and preclinical mouse models, it remains to be answered if a synergistic effect or enhanced induction of apoptosis can be achieved when PL is combined with another drug.…”

mentioning

confidence: 99%

Piperlongumine and immune cytokine TRAIL synergize to promote tumor death

Sharkey

King

2015

Sci Rep

View full text Add to dashboard Cite

Malignant transformation results in increased levels of reactive oxygen species (ROS). Adaption to this toxic stress allows cancer cells to proliferate. Recently, piperlongumine (PL), a natural alkaloid, was identified to exhibit novel anticancer effects by targeting ROS signaling. PL induces apoptosis specifically in cancer cells by downregulating several anti-apoptotic proteins. Notably, the same anti-apoptotic proteins were previously found to reduce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in cancer cells. Therefore, we reasoned that PL would synergize with TRAIL to stimulate potent apoptosis in cancer cells. We demonstrate for the first time that PL and TRAIL exhibit a synergistic anti-cancer effect in cancer cell lines of various origins. PL resulted in the upregulation of TRAIL receptor DR5, which potentiated TRAIL-induced apoptosis in cancer cells. Furthermore, such upregulation was found to be dependent on ROS and the activation of JNK and p38 kinases. Treatment with combined PL and TRAIL demonstrated significant anti-proliferative effects in a triple-negative breast cancer MDA-MB-231 xenograft model. This work provides a novel therapeutic approach for inducing cancer cell death. Combination of PL and TRAIL may suggest a novel paradigm for treatment of primary and metastatic tumors.

show abstract

“…Efforts have been made to apply nanomedicine in cancer treatment to improve the efficiency of anticancer regimens (17,18,34,35). In the present study, SWCNTs were used as the carrier of oxygen, which was expected to increase the sensitivity of cancer cells to chemotherapy and radiotherapy.…”

Section: Discussionmentioning

confidence: 99%

Increased chemosensitivity and radiosensitivity of human breast cancer cell lines treated with novel functionalized single-walled carbon nanotubes

et al. 2016

View full text Add to dashboard Cite

Hypoxia is a major cause of treatment resistance in breast cancer. Single-walled carbon nanotubes (SWCNTs) exhibit unique properties that make them promising candidates for breast cancer treatment. In the present study, a new functionalized single-walled carbon nanotube carrying oxygen was synthesized; it was determined whether this material could increase chemosensitivity and radiosensitivity of human breast cancer cell lines, and the underlying mechanisms were investigated. MDA-MB-231 cells growing in folic acid (FA) free medium, MDA-MB-231 cells growing in medium containing FA and ZR-75-1 cells were treated with chemotherapy drugs or radiotherapy with or without tombarthite-modified-FA-chitosan (R-O2-FA-CHI)-SWCNTs under hypoxic conditions, and the cell viability was determined by water-soluble tetrazolium salts-1 assay. The cell surviving fractions were determined by colony forming assay. Cell apoptosis induction was monitored by flow cytometry. Expression of B-cell lymphoma 2 (Bcl-2), survivin, hypoxia-inducible factor 1-α (HIF-1α), multidrug resistance-associated protein 1 (MRP-1), P-glycoprotein (P-gp), RAD51 and Ku80 was monitored by western blotting. The novel synthesized R-O2-FA-CHI-SWCNTs were able to significantly enhance the chemosensitivity and radiosensitivity of human breast cancer cell lines and the material exhibited its expected function by downregulating the expression of Bcl-2, survivin, HIF-1α, P-gp, MRP-1, RAD51 and Ku80.

show abstract

Doxorubicin and Lapatinib Combination Nanomedicine for Treating Resistant Breast Cancer

Cited by 74 publications

References 57 publications

Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer

Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer

Piperlongumine and immune cytokine TRAIL synergize to promote tumor death

Increased chemosensitivity and radiosensitivity of human breast cancer cell lines treated with novel functionalized single-walled carbon nanotubes

Contact Info

Product

Resources

About